Doxazosin (mesylate)

Doxazosin mesylate (UK 33274 mesylate) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

Product Specifications

CAS Number

[77883-43-3]

Product Name Alternative

UK 33274 (mesylate)

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H361, H373

Target

Adrenergic Receptor; Autophagy; Mitophagy

Type

Reference compound

Related Pathways

Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Doxazosin-mesylate.html

Purity

98.49

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OC5=CC=CC=C5OC4.CS(=O)(O)=O

Molecular Formula

C24H29N5O8S

Molecular Weight

547.58

Precautions

H315, H319, H335, H361, H373

References & Citations

[1]Sun, J.A., et al., Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro. Acta Pharmacol Sin, 2013. 34 (12) : p. 1568-74.|[2]D'Eletto, R.D. and N.B. Javitt, Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol, 1989. 13 Suppl 2: p. S1-4; discussion S4.|[3]Miura, Y. and K. Yoshinaga, Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J, 1988. 116 (6 Pt 2) : p. 1785-9.